Clinical Trial Update: CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS [Phase 1]

View source ↗

Summary

This entry provides a status update on a Phase 1 multiple-dose safety and tolerability study (CC100) in subjects with amyotrophic lateral sclerosis. Sponsor: Ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• CC100

Snippet

Sponsor: Chemigen, LLC | Conditions: Amyotrophic Lateral Sclerosis | Phase 1 | Status: UNKNOWN